{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T15:18:20Z","timestamp":1791818300705,"version":"4.3.4"},"reference-count":58,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T00:00:00Z","timestamp":1705536000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.clml.2024.01.007","type":"journal-article","created":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T17:11:31Z","timestamp":1705597891000},"page":"364-374","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Venetoclax and Cobimetinib in Relapsed\/Refractory AML: A Phase 1b Trial"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9347-2212","authenticated-orcid":false,"given":"Marina Y.","family":"Konopleva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique","family":"Dail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naval G.","family":"Daver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2118-6302","authenticated-orcid":false,"given":"Jacqueline S.","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4921-5809","authenticated-orcid":false,"given":"Brian A.","family":"Jonas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen W.L.","family":"Yee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin R.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Vey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarit","family":"Assouline","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gail J.","family":"Roboz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Paolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel A.","family":"Pollyea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agostino","family":"Tafuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph M.","family":"Brandwein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Pigneux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bayard L.","family":"Powell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Fenaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca L.","family":"Olin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Visani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Martinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maika","family":"Onishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weize","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8930-1587","authenticated-orcid":false,"given":"Diana R.","family":"Dunshee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0196-9852","authenticated-orcid":false,"given":"Habib","family":"Hamidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion G.","family":"Ott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0134-4927","authenticated-orcid":false,"given":"Wan-Jen","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Andreeff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2024.01.007_bib0001","unstructured":"National Cancer Institute. Cancer stat facts: leukemia \u2014 acute myeloid leukemia (AML). 2020. Accessed: March 17, 2023. Available at: https:\/\/seer.cancer.gov\/statfacts\/html\/amyl.html."},{"key":"10.1016\/j.clml.2024.01.007_bib0002","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1182\/blood-2005-09-3724","article-title":"Age and acute myeloid leukemia","volume":"107","author":"Appelbaum","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.01.007_bib0003","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1002\/ajh.25162","article-title":"Very poor long-term survival in past and more recent studies for relapsed AML patients: the ECOG-ACRIN experience","volume":"93","author":"Ganzel","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2024.01.007_bib0004","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S1470-2045(15)00201-6","article-title":"Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study","volume":"16","author":"Ravandi","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2024.01.007_bib0005","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1200\/JCO.2013.52.8562","article-title":"International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed\/refractory acute myeloid leukemia","volume":"32","author":"Roboz","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2024.01.007_bib0006","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1182\/bloodadvances.2018016121","article-title":"Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort","volume":"2","author":"Stahl","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2024.01.007_bib0007","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.clml.2024.01.007_bib0008","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","article-title":"Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia","volume":"6","author":"Konopleva","year":"2016","journal-title":"Cancer Discov"},{"key":"10.1016\/j.clml.2024.01.007_bib0009","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1158\/0008-5472.CAN-11-1515","article-title":"Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition","volume":"72","author":"Hoeflich","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2024.01.007_bib0010","unstructured":"Genentech. U.S. prescribing information: COTELLIC (cobimetinib). 2022. Accessed: March 17, 2023. Available at: https:\/\/www.gene.com\/download\/pdf\/cotellic_prescribing.pdf."},{"key":"10.1016\/j.clml.2024.01.007_bib0011","unstructured":"European Medicines Agency. Summary of product characteristics: COTELLIC (cobimetinib). 2023. Accessed: March 17, 2023. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/cotellic-epar-product-information_en.pdf."},{"key":"10.1016\/j.clml.2024.01.007_bib0012","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1002\/cncr.29986","article-title":"Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies","volume":"122","author":"Borthakur","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2024.01.007_bib0013","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1158\/1078-0432.CCR-13-1311","article-title":"Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial","volume":"20","author":"Jain","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2024.01.007_bib0014","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.clml.2018.12.009","article-title":"Phase II trial of MEK inhibitor binimetinib (MEK162) in RAS-mutant acute myeloid leukemia","volume":"19","author":"Maiti","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2024.01.007_bib0015","doi-asserted-by":"crossref","first-page":"697","DOI":"10.3324\/haematol.2018.205534","article-title":"Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models","volume":"105","author":"Han","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2024.01.007_bib0016","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.2174\/1381612054546842","article-title":"Beyond single pathway inhibition: MEK inhibitors as a platform for the development of pharmacological combinations with synergistic anti-leukemic effects","volume":"11","author":"Milella","year":"2005","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.clml.2024.01.007_bib0017","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1182\/blood.V99.9.3461","article-title":"Synergistic induction of apoptosis by simultaneous disruption of the BCL-2 and MEK\/MAPK pathways in acute myelogenous leukemia","volume":"99","author":"Milella","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.01.007_bib0018","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/leu.2011.287","article-title":"MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1\/BIM complex","volume":"26","author":"Konopleva","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2024.01.007_bib0019","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1182\/blood.V91.3.991","article-title":"Elevated expression of the apoptotic regulator MCL-1 at the time of leukemic relapse","volume":"91","author":"Kaufmann","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.01.007_bib0020","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/s41392-022-00958-4","article-title":"Correction: activation of RAS\/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia","volume":"7","author":"Zhang","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.clml.2024.01.007_bib0021","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1182\/blood.2022016362","article-title":"Venetoclax and idasanutlin in relapsed\/refractory AML: a nonrandomized, open-label phase 1b trial","volume":"141","author":"Daver","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.01.007_bib0022","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/S1470-2045(16)30122-X","article-title":"Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial","volume":"17","author":"Ascierto","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2024.01.007_bib0023","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.01.007_bib0024","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","article-title":"Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia","volume":"21","author":"Cheson","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2024.01.007_bib0025","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.1182\/blood-2015-08-664649","article-title":"Integrated genomic DNA\/RNA profiling of hematologic malignancies in the clinical setting","volume":"127","author":"He","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.01.007_bib0026","article-title":"Mechanisms of venetoclax resistance and solutions","volume":"12","author":"Liu","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.clml.2024.01.007_bib0027","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","article-title":"The molecular signatures database (MSigDB) hallmark gene set collection","volume":"1","author":"Liberzon","year":"2015","journal-title":"Cell Syst"},{"key":"10.1016\/j.clml.2024.01.007_bib0028","unstructured":"Genentech. U.S. prescribing information: VENCLEXTA\u00ae (venetoclax). 2022. Accessed: June 12, 2023. Available at: https:\/\/www.rxabbvie.com\/pdf\/venclexta.pdf."},{"key":"10.1016\/j.clml.2024.01.007_bib0029","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1007\/s10637-016-0374-3","article-title":"A first-in-human phase I study to evaluate the MEK1\/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors","volume":"34","author":"Rosen","year":"2016","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.clml.2024.01.007_bib0030","doi-asserted-by":"crossref","first-page":"e404","DOI":"10.3324\/haematol.2018.188094","article-title":"Efficacy of the combination of venetoclax and hypomethylating agents in relapsed\/refractory acute myeloid leukemia","volume":"103","author":"Aldoss","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2024.01.007_bib0031","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.649209","article-title":"Outcomes of adults with relapsed\/refractory acute myeloid leukemia treated with venetoclax plus hypomethylating agents at a comprehensive cancer center","volume":"11","author":"Tenold","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.clml.2024.01.007_bib0032","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1159\/000525566","article-title":"A phase II study of azacitidine, venetoclax, and trametinib in relapsed or refractory acute myeloid leukemia harboring RAS pathway-activating mutations","volume":"145","author":"Desikan","year":"2022","journal-title":"Acta Haematol"},{"key":"10.1016\/j.clml.2024.01.007_bib0033","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.leukres.2014.11.009","article-title":"Azacitidine for the treatment of relapsed and refractory AML in older patients","volume":"39","author":"Itzykson","year":"2015","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2024.01.007_bib0034","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/sj.cr.7290105","article-title":"MAPK signal pathways in the regulation of cell proliferation in mammalian cells","volume":"12","author":"Zhang","year":"2002","journal-title":"Cell Res"},{"key":"10.1016\/j.clml.2024.01.007_bib0035","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.biocel.2010.09.018","article-title":"Functions and regulation of the 70kDa ribosomal S6 kinases","volume":"43","author":"Fenton","year":"2011","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.clml.2024.01.007_bib0036","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/ng1987","article-title":"A module of negative feedback regulators defines growth factor signaling","volume":"39","author":"Amit","year":"2007","journal-title":"Nat Genet"},{"key":"10.1016\/j.clml.2024.01.007_bib0037","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1242\/jcs.036319","article-title":"Positive- and negative-feedback regulations coordinate the dynamic behavior of the RAS-RAF-MEK-ERK signal transduction pathway","volume":"122","author":"Shin","year":"2009","journal-title":"J Cell Sci"},{"key":"10.1016\/j.clml.2024.01.007_bib0038","doi-asserted-by":"crossref","first-page":"22033","DOI":"10.1074\/jbc.274.31.22033","article-title":"Multiple RAS effector pathways contribute to G(1) cell cycle progression","volume":"274","author":"Gille","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1016\/j.clml.2024.01.007_bib0039","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102137","article-title":"MEK inhibitor resistance mechanisms and recent developments in combination trials","volume":"92","author":"Kun","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.clml.2024.01.007_bib0040","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1158\/2159-8290.CD-13-0642","article-title":"Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy","volume":"4","author":"Shi","year":"2014","journal-title":"Cancer Discov"},{"key":"10.1016\/j.clml.2024.01.007_bib0041","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41408-023-00830-w","article-title":"Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimetics","volume":"13","author":"Carter","year":"2023","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2024.01.007_bib0042","doi-asserted-by":"crossref","first-page":"58","DOI":"10.3324\/haematol.2020.260331","article-title":"Targeting MCL-1 dysregulates cell metabolism and leukemia-stroma interactions and re-sensitizes acute myeloid leukemia to BCL-2 inhibition","volume":"107","author":"Carter","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2024.01.007_bib0043","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1002\/ajh.26314","article-title":"Development of TP53 mutations over the course of therapy for acute myeloid leukemia","volume":"96","author":"Alwash","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2024.01.007_bib0044","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1038\/sj.leu.2402608","article-title":"Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteins","volume":"16","author":"Konopleva","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2024.01.007_bib0045","doi-asserted-by":"crossref","first-page":"4048","DOI":"10.1200\/JCO.22.00602","article-title":"Venetoclax plus gilteritinib for FLT3-mutated relapsed\/refractory acute myeloid leukemia","volume":"40","author":"Daver","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2024.01.007_bib0046","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1158\/2159-8290.CD-18-1453","article-title":"Clonal selection with RAS pathway activation mediates secondary clinical resistance to selective FLT3 inhibition in acute myeloid leukemia","volume":"9","author":"McMahon","year":"2019","journal-title":"Cancer Discov"},{"key":"10.1016\/j.clml.2024.01.007_bib0047","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1182\/bloodadvances.2021006489","article-title":"Molecular profile of FLT3-mutated relapsed\/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib","volume":"6","author":"Smith","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2024.01.007_bib0048","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1038\/s41467-021-22874-x","article-title":"Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia","volume":"12","author":"Wang","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.clml.2024.01.007_bib0049","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1182\/blood-2018-08-869008","article-title":"Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib","volume":"133","author":"Stein","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.01.007_bib0050","doi-asserted-by":"crossref","first-page":"894","DOI":"10.3324\/haematol.2020.252569","article-title":"Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens","volume":"106","author":"Maiti","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2024.01.007_bib0051","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1182\/blood.2019003988","article-title":"Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML","volume":"135","author":"DiNardo","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.01.007_bib0052","doi-asserted-by":"crossref","first-page":"5565","DOI":"10.1182\/bloodadvances.2021005538","article-title":"Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia","volume":"5","author":"Cherry","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2024.01.007_bib0053","doi-asserted-by":"crossref","first-page":"3186","DOI":"10.1038\/s41375-020-0972-0","article-title":"Pan-RAF inhibition induces apoptosis in acute myeloid leukemia cells and synergizes with BCL2 inhibition","volume":"34","author":"Tambe","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2024.01.007_bib0054","article-title":"Allosteric SHP2 inhibition increases apoptotic dependency on BCL2 and synergizes with venetoclax in FLT3- and KIT- mutant AML","volume":"4","author":"Popescu","year":"2023","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.clml.2024.01.007_bib0055","doi-asserted-by":"crossref","first-page":"3511","DOI":"10.3390\/cancers12123511","article-title":"Pan-RAF inhibition shows anti-leukemic activity in RAS-mutant acute myeloid leukemia cells and potentiates the effect of sorafenib in cells with FLT3 mutation","volume":"12","author":"Khoury","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.clml.2024.01.007_bib0056","doi-asserted-by":"crossref","first-page":"1","DOI":"10.33696\/Signaling.4.085","article-title":"Augmenting venetoclax activity through signal transduction in AML","volume":"4","author":"Bouligny","year":"2023","journal-title":"J Cell Signal"},{"key":"10.1016\/j.clml.2024.01.007_bib0057","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s41586-021-03515-1","article-title":"ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma","volume":"594","author":"Yen","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.clml.2024.01.007_bib0058","doi-asserted-by":"crossref","first-page":"12370","DOI":"10.1038\/s41375-022-01541-0","article-title":"RAS activation induces synthetic lethality of MEK inhibition with mitochondrial oxidative metabolism in acute myeloid leukemia","volume":"36","author":"Decroocq","year":"2022","journal-title":"Leukemia"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024000363?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024000363?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T13:02:08Z","timestamp":1716987728000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265024000363"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":58,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S2152265024000363"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2024.01.007","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Venetoclax and Cobimetinib in Relapsed\/Refractory AML: A Phase 1b Trial","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2024.01.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}